GlassScriptPhysician profile
Katana M Boyd
NPI 1073052296
$4,157.61
in general payments reported to CMS, 2019-2025
28 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $1,799 · 2023: $1,071 · 2024: $392 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,288.27 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.51 | 2022-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $246.36 | 2023-2024 | Xtampza, Belbuca |
| Pfizer INC. | $213.98 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.13 | 2022 | |
| Amgen INC. | $126.74 | 2022 | |
| Lilly USA, LLC | $70.55 | 2022-2025 | Mounjaro, Emgality, Reyvow |
| Valinor Pharma, LLC | $70.09 | 2023-2024 | Movantik |
| Impel Pharmaceuticals INC. | $58.28 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $51.19 | 2023 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $45.53 | 2022-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $44.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.09 | 2025 | |
| Abbott Laboratories | $41.28 | 2021-2023 | Proclaim |
| Sunovion Pharmaceuticals INC. | $33.08 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.22 | 2025 | |
| Sumitomo Pharma America, INC. | $24.92 | 2025 | Gemtesa |
| Amneal Pharmaceuticals LLC | $24.83 | 2022 | |
| Lundbeck LLC | $22.01 | 2023 | Vyepti |
| Supernus Pharmaceuticals, INC. | $20.50 | 2022 | |
| Novo Nordisk INC | $19.62 | 2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $18.74 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $18.08 | 2025 | Cologuard Collection Kit |
| Si-Bone, INC. | $16.58 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.56 | 2023 | Horizant |
| Glaxosmithkline, LLC. | $15.72 | 2025 | Penmenvy, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $15.48 | 2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Protega Pharmaceutials INC | $14.94 | 2024 | Roxybond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katana Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.